Kornimate/medical-research-clean huggingface dataset:
compassionate use study of nhwd-870 in patients with advanced solid tumors or lymphomas carrying nut rearrangement

Conditions: Advanced Solid Tumors or Lymphomas

Summary: the nhwd-870 phase i clinical trial evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics in patients with advanced tumors. the objectives of this retrospective study were to preliminarily evaluate the anti-tumor efficacy of nhwd-870 hcl in patients with advanced solid tumors or lymphomas and to preliminarily evaluate biomarkers associated with the efficacy of nhwd-870 hcl in the treatment of patients with advanced solid tumors or lymphomas, to provide a basis for identifying the enriched population for the late-stage trial.


Eligibility criteria:
inclusion criteria: 1. signing an informed consent form; 2. patients with advanced solid tumors or lymphomas definitively diagnosed by pathology; 3. age ≥18 and ≤75 years; 4. eastern cooperative oncology group (ecog) score physical status score of 0 to 1; 5. expected survival of \>3 months; 6. nut positive confirmed by molecular testing. exclusion criteria: subjects who meet one or more of the following criteria will be excluded: 1. other serious complications (such as uncontrolled infection, myocardial infarction within 6 months, high blood pressure (≥ 160/100mmhg) and thromboembolic disease that cannot be controlled by drug intervention, etc.); 2. the adverse reactions of previous anti-tumor therapy have not been restored to ctcae 5.0 ≤ grade1 (except for hair loss, anemia and other toxicities judged by researchers to be unsafe); 3. history of substance abuse; 4. inability to take drugs due to dysphagia (except for patients who receive nutrients through a gastric tube due to dysphagia), or conditions that the investigator determines seriously affect gastrointestinal absorption; 5. patients with a history of other serious systemic diseases who are judged by the investigator to be unsuitable for participating in clinical trials; 6. alcoholics or those who drink more than 28 units of alcohol per week (1 unit = 285 ml of beer or 25 ml of spirits or 1 glass of wine); 7. suffering from uncontrollable mental illness; 8. pregnant or lactating women, or patients of childbearing age (including male subjects) with pregnancy plans; 9. active hepatitis b (viral titer \>103), hepatitis c or hiv ( ); 10. long-term treatment with high-dose corticosteroids or other immunosuppressants, such as those who have undergone organ transplantation, or those who have received systemic glucocorticoids (such as prednisone\> 10 mg/day or equivalent drugs) or other immunosuppressant therapy within 14 days before the first use of the study drug; exceptions are given for topical, ocular, intra-articular, intranasal and inhaled corticosteroid therapy; short-term use of glucocorticoids for prophylaxis (e.g., prevention of contrast allergy); 11. the investigator believes that the subject is not suitable to participate in this clinical study for other objective reasons.
most people with low back pain have associated cervicothoracic musculoskeletal dysfunction: an observational study

Conditions: Low Back Pain

Summary: in general , the diagnosis of back pain can be broken into three major categories: mechanical ( osteoarthritis , spinal stenosis , spondylolisthesis) ; non- mechanical ( tumor , infection , inflammatory arthritis ) and miscellaneous (osteoporosis , psychosomatic disorders , neuropathic joints , visceral diseases ). although 98% of lbp may be caused by mechanical factors, it is the other 2% caused by malignancy, infection, visceral diseases and other red herrings that must be considered most seriously. the investigators have observed in their practice that lateral pressure on 5th lumbar vertebra sometimes gives rise to cervicothoracic pain and central pa pressure over cervicothoracic spines reproduce original low back and leg pain. so the question arises whether cervico-thoracic dysfunction is associated with low back pain with or without radiation to lower extremities?


Eligibility criteria:
inclusion criteria: * mechanical low back pain with or without radiation to lower limb. exclusion criteria: * any recent trauma or fractures to cervico-thoracic junction, osteoporosis, inflammatory arthritis, tuberculosis, bone disease, congenital deformity * vascular disorders * rapidly progressing neurological deficits * sudden onset of neurological deficits and all red flags to manual therapy.
temporomandibular dysfunction and cervical posture

Conditions: Temporomandibular Dysfunction

Summary: the aim of this research was to determine the existence of a correlation between the degree of temporomandibular dysfunction and cervical posture in different occlusal classes in adolescents. a cross-section, observational study was carried out, in which 296 adolescents took part. for the evaluation, the patients were divided into groups according to the presence and severity of the temporomandibular dysfunction, using a questionnaire and occlusal angle classification. the posture analysis was carried out using photogrammetry and the software alcimage® to measure the predefined angle based on the protuberances of the spinous process of the 7th cervical vertebra (c7), manubrium of the sternum and mentum vertex.

the evaluation of signs and symptoms of tmd was obtained from a questionnaire (15) which includes information regarding difficulties opening the mouth and movement of the mandible, pains in the head, nape of the neck, neck or joint regions, noise in the temporomandibular joints, and the habit of clenching or grinding the teeth. the questionnaire is comprised of 10 questions with possible answers of yes (10 points), sometimes (5 points) and no (0 points). for each question, only one answer can be checked. the total score is used to classify the severity of the tmd as severe (70 to 100 points), moderate (45 to 65), mild (20 to 40) and no dysfunction (0 to 15). the clinical (visual) assessment of head posture was conducted using a postural grid. each subject was asked to remain in his or her normal posture, in a standing position. the self balance position was used to standardize the posture of each subject, asking them to look straight ahead, parallel to the floor, keeping the gaze horizontal

Eligibility criteria:
inclusion criteria: * adolescents, aged between 10 and 20 years. as criteria for inclusion, age group and the presence of first permanent molar exclusion criteria: * individuals undergoing orthodontic treatment, those with absent first molars and cases where it was impossible to clinically evaluate the occlusion were excluded.

Keywords: temporomandibular dysfunction posture
a study of itraconazole in the prevention of histoplasmosis, a fungal infection, in hiv-infected patients

Conditions: HIV Infections; Histoplasmosis

Summary: to assess the safety and efficacy of itraconazole versus placebo for prevention of histoplasmosis in hiv-infected patients with cd4 counts \< 150 cells/mm3 who reside where histoplasmosis is endemic. to assess the safety and efficacy of itraconazole for preventing other debilitating fungal infections, such as cryptococcosis, aspergillosis, recalcitrant oropharyngeal or vaginal candidiasis, and recurrent esophageal candidiasis.


Eligibility criteria:
inclusion criteria patients must have: * hiv infection. * residence in an area endemic for h. capsulatum. * absolute cd4 count \< 150 cells/mm3. * no current or past active histoplasmosis. * no other active fungal infection. * life expectancy of at least 1 year. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * life-threatening infection or malignancy other than cutaneous kaposi's sarcoma. * inability to take oral medication. concurrent medication: excluded: * systemically-active antifungals. * investigational drugs (expanded access drugs are acceptable). * rifampin. * rifabutin. * terfenadine. * astemizole. * phenobarbital. * phenytoin. * carbamazepine. * h2 blockers. * omeprazole. * continual antacids. patients with the following prior conditions are excluded: history of intolerance to imidazole or azole compounds. prior medication: excluded within 1 month prior to study entry: * investigational drugs (expanded access drugs are acceptable). excluded within 15 days prior to study entry: * rifampin. * rifabutin. * terfenadine. * astemizole. * phenobarbital. * phenytoin. * carbamazepine.

Keywords: itraconazole histoplasmosis acquired immunodeficiency syndrome
the effect of intradialytic parenteral nutrition on nutritional status and quality of life in hemodialysis patients

Conditions: End Stage Renal Disease; Malnutrition; Sarcopenia; Hemodialysis Complication

Summary: protein-energy wasting (pew), a hypercatabolic state characterized by loss of muscle mass and fuel reserves, is highly prevalent in hemodialysis patients. nutritional status and body composition are closely linked to morbidity, mortality and quality of life. lean tissue mass (ltm) appears to be the best read-out for the association between nutritional status and outcomes. intradialytic parenteral nutrition (idpn) is occasionally used with the aim to reduce loss of ltm, but its efficacy has not been established. the goal of this study is to study the effect of idpn on changes in ltm in hemodialysis patients.


Eligibility criteria:
inclusion criteria: * undergoing chronic hemodialysis exclusion criteria: * life expectancy \< 6 months * planned kidney transplant within 4 months * severe overhydration leading to respiratory insufficiency * parenteral nutrition within four weeks prior to screening * severe hepatic insufficiency * pregnancy * unipolar pacemaker with a very low sensitivity threshold * active treatment for infection * acute myocardial infarction * circulatory shock * hypersensitivity for any olimel n12 ingredient or excipient
the effects of early and late injection of botulinum toxin type a on upper limb function in patients with stroke

Conditions: Stroke

Summary: the aim of this study is to determine whether early use of onabotulinumtoxina is more effective to improve functional outcomes of upper limb in patients with stroke.

many patients surviving stroke have significant impairment of function in the affected upper limb due to the development of spasticity. botulinum toxin type a injection is a powerful treatment option for control of spasticity. in this study, the patients will be randomly assigned into three groups: early onabotulinumtoxina group will receive onabotulinumtoxina injection when their spasticity develop, late onabotulinumtoxina group will have injection at 6 months after emergence of spasticity, the third group will not have onabotulinumtoxina intervention. the aim of this randomized controlled study is to evaluate the effects of early and late injection of botulinum toxin type a on upper limb function in patients with stroke.

Eligibility criteria:
inclusion criteria: * stroke affecting one body side * spasticity develops after stroke exclusion criteria: * musculoskeletal conditions that affected upper limb function prior to stroke * concurrent use of anti-spasticity medications * patients with neuromuscular junction or myopathic disorders such as myasthenia gravis or others * patients with a known allergy to any onabotulinumtoxina or to any of the excipients of onabotulinumtoxina (such as human serum albumin) * patients who are pregnant or may become pregnant at the time of the proposed injection

Keywords: stroke spasticity onabotulinumtoxina
comparison of efficacy between fractional microneedling radiofrequency and bipolar radiofrequency for acne scar

Conditions: Acne; Scar

Summary: compare the efficacy and safety profile of microneedling radiofrequency and that of bipolar radiofrequency treatment for acne scar.

efficacy and safety of microneedling radiofrequency for acne scar efficacy and safety bipolar radiofrequency treatment for acne scar compare the efficacy and safety profile of microneedling radiofrequency and that of bipolar radiofrequency treatment for acne scar

Eligibility criteria:
inclusion criteria: * moderate acne scar * mild to moderate acne lesions exclusion criteria: * taking acne medication oral drugs within 2 months topical drugs within 2 weeks * taken anu procedures for acne scar within 6 months * taking steroid,nonsteroidal antiinflammtory drugs, isotretinoin * underlying diabetes mellitus, keloid, or any malignancy

Keywords: acne acne scar microneedling radiofrequency bipolar radiofrequency
177lu-psma-eb-01 in patients with metastatic castration-resistant prostate cancer

Conditions: Metastatic Castration-resistant Prostate Cancer

Summary: this is a pilot study to assess the safety and measure image-based absorbed dose of 177lu-psma-eb-01, a new psma-specific radiopharmaceutical, in patients with metastatic castration resistant prostate cancer (mcrpc) who will undergo radioligand therapy (rlt). all patients underwent 68ga-psma and 18f-fdg pet/ct for selection and were randomly divided into three groups of 3 people each.the three groups received an approximately 1.11 gbq (30mci), 1.85 gbq (50 mci) and 2.59 gbq (70mci) of 177lu-psma-eb-01 up to 2 cycles, respectively.

prostate cancer is the most frequent malignant tumor in men worldwide. prostate-specific membrane antigen (psma), is a surface molecule specifically expressed by prostate tumors which was shown to be a valid target for radiotherapy. 177lu-psma-617, a urea-based compound, provide an effective target for the treatment of metastatic castration-resistant prostate cancer. however, a major problem in the therapeutic use of 177lu-psma-617 has been its short half-life and fast rate of clearance. the investigators designed and synthesized a new radiopharmaceutical, named 177lu-psma-eb-01. eb（evans blue）can bind to albumin to slow down its plasma clearance rate, thereby increasing tumor accumulation and reducing the total dosage of lu-177. hence, eb-psma-01 may be an option for consideration due to limited supply of lu-177, by which more patients may be benefited by this version of 177lu-eb-psma-01. this study was designed to investigate the safety, dosimetry and preliminary effects of 177lu-eb-psma-01 in patients with metastatic castration resistant prostate cancer.

Eligibility criteria:
inclusion criteria: * progressive metastatic castration-resistant prostate cancer * tumors with high psma expression confirmed on 68ga-psma pet/ct exclusion criteria: * a serum creatinine level of more than 150 μmol per liter * a hemoglobin level of less than 10.0 g/dl * a white-cell count of less than 4.0× 109/l * a platelet count of less than 100 × 109/l * a total bilirubin level of more than 3 times the upper limit of the normal range * a serum albumin level of more than 3.0 g per deciliter * cardiac insufficiency
percutaneous treatment of long native coronary lesions with drug-eluting stent-iii (long-des-iii)

Conditions: Coronary Artery Disease

Summary: this randomized study is a multi-center, randomized, study to compare the efficacy of sirolimus versus everolimus-eluting stent implantation for long coronary lesions.

following angiography, patients with significant diameter stenosis \>50% and lesion length (\> 25mm) requiring single or multiple long-stent placement (total stent length \>28mm) by visual estimation and eligible for long-des iii trial inclusion and exclusion criteria will be randomized 1:1 to a) sirolimus-eluting and b) everolimus-eluting stent by the stratified randomization method.

Eligibility criteria:
inclusion criteria: * the patient must be at least 18 years of age. * significant native coronary artery stenosis (\>50% by visual estimate) with lesion length of more than 25mm, which requiring single or multiple long stent placement (\>=28mm) * patients with silent ischemia, stable or unstable angina pectoris, ad non-st-elevation myocardial infarction * the patient or guardian agrees to the study protocol and the schedule of clinical and angiographic follow-up, and provides informed, written consent, as approved by the appropriate institutional review board/ethical committee of the respective clinical site. exclusion criteria: * any contraindication to any of the following medications: aspirin, heparin, clopidogrel, stainless steel, contrast agents, sirolimus, or everolimus. * an elective surgical procedure is planned that would necessitate interruption of antiplatelet drugs during the first 6 months post enrollment. * acute st-segment-elevation mi or cardiogenic shock * terminal illness with life expectancy \<1 year * patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period. * in-stent restenosis at target vessel (either bare metal stent or drug-eluting stent segment, non-target vessel isr is permitted) * patients with ef\<30%. * serum creatinine level \>=3.0mg/dl or dependence on dialysis. * patients with left main stem stenosis (\>50% by visual estimate).

Keywords: coronary artery disease stent
effectiveness of different physiotherapy practices in temporomandibular disorders

Conditions: Temporomandibular Disorder

Summary: the aim of the study is to examine the effect of high voltage electrical stimulation on pain, temporomandibular joint mobility, cervical mobility, head position, tender points and joint sounds in individuals with temporomandibular disorders.

28 individuals who meet the tmer / research diagnostic criteria classification will be randomly divided into 2 groups. exercise with high voltage electrical stimulation (yves) will be applied to the 1st group and only exercise will be applied to the 2nd group. the second group will be the control group of the study. both groups will be informed about the disease before starting the study before the treatment and patient education will be given about the situations that need attention. again, 2 groups will be given an exercise program from the day they start the treatment, 3 times a week for 4 weeks during the treatment. as sociodemographic information of the individuals, age, gender, height, weight, body mass index, marital and educational status, occupation, smoking and alcohol use, patient history, family history and complaint sides will be recorded. before starting treatment, individuals will be evaluated for pain, temporomandibular joint mobility, cervical mobility, tender points, and joint sounds: 1. pain with visual analogue scale (vas), 2. tmj mobility with a ruler, 3. cervical mobility with c-rom (cervical range of motion) inclinometer, 4. head position with universal goniometer and imagej software, 5. sensitive points with algometer, 6. joint sounds will be evaluated as present / absent as a result of the evaluation of movements in all directions (maximum mouth opening, right / left lateral excursions, protrusion and retrusion). after 4 weeks of treatment, the measurements will be repeated.

Eligibility criteria:
inclusion criteria: * individuals who have been diagnosed with tmer, * comply with the tmd / rdc classification, * have class i-ii-iii occlusion, * volunteer to participate in the study, and fill out the informed consent form will be included. exclusion criteria: * acute trauma, * surgery history, * neurological or psychiatric conditions, * trigeminal or postherpatic neuralgia, * dental or orofacial infection, * intraoral infection or tumor, * oligodontics and anadontics, * high voltage electrical stimulation contraindications, * any disease diagnosed in the shoulder and neck areas, * receiving another treatment and, * individuals under the age of 18 will be excluded in the study.

Keywords: high voltage stimulation temporomandibular disorders temporomandibular joint cervical spine pain
observational study of a cohort of patients with hereditary epidermolysis bullosa

Conditions: Epidermolysis Bullosa

Summary: hereditary epidermolysis bullosa (ebh) are rare dermatologic diseases characterized by cutaneous and mucosa fragility. oral manifestations of few small cohort have been published. the main objective of this multicentric cohort study first in europe was to report the oral status of these patients that were consulted in the mrdrc of this disease in nice (france), toulouse (france) and louvain (belgium). then a correlation between the oral characteristics and the ebh type will be made, in order to facilitate the management of patient care and the prevention program that can be established to improve their oral health.


Eligibility criteria:
inclusion criteria: * patient with ebh * patient consent for examination and use the clinical data for publication purpose exclusion criteria: -
effects of music and affirmation recital in women with breast cancer

Conditions: Breast Cancer

Summary: the aim of this study is to determine the effect of music and affirmation recitals on symptom control, psychological resilience and anxiety levels in women with breast cancer.

introduction: music therapy is attracting attention today because it is a person-centered approach that does not require any special skills and/or significant financial investments. method: the aim of this study is to determine the effect of music and affirmation recitals on symptom control, psychological resilience and anxiety levels in women with breast cancer. this study will be conducted using a randomized controlled trial design. it is planned to include 75 women in total, 25 patients in the music recital group, 25 patients in the music and affirmation group and 25 patients in the control group. data in the study will be collected using the introductory information form, edmonton symptom diagnostic scale, state anxiety scale and psychological resilience scale. conclusion: it is thought that the findings obtained in this study will contribute to the use of music and affirmation, which are cheap, effective and easily applicable methods, in chemotherapy units as a method to help reduce patients' anxiety. the study is expected to reduce the symptoms of breast cancer patients and reduce their anxiety levels

Eligibility criteria:
inclusion criteria: * those diagnosed with breast cancer * those who have received at least 1 course of chemotherapy * those over the age of 18 * those who agree to participate in the study exclusion criteria: * those who are not receiving curative chemotherapy * those who do not have a phone to listen to music and affirmations * those who do not agree to participate in the study * those with mental and neuropsychiatric diseases

Keywords: chemotherapy music
effects of different early intensive therapies on long-term β-cell function

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to investigate and evaluate the effects of different oral antihyperglycaemic agents combined with short-term continuous subcutaneous insulin infusion(csii)(1.csii alone; 2.metformin and pioglitazone combined with csii; 3. sitagliptin combined with csii) on long-term glycemic control and β-cell function in newly diagnosed type 2 diabetic patients.


Eligibility criteria:
inclusion criteria: * newly diagnosed type 2 diabetes * fasting blood glucose (fbg) level ranging from 7.0～16.7 mmol/l * body mass index (bmi) ranging from21～35kg/m2 * antihyperglycaemic and antihyperlipidemic medication-naive patients exclusion criteria: * having any severe acute or chronic diabetic complications * renal dysfunction, blood creatinine≥150µmol/l * blood aminotransferase level rising up(more than 2 times of the upper normal limit of alt) * • any severe cardiac disease including congestive cardiac failure, unstable angina or myocardial infarct in 12 months * chronic or acute pancreatic disease * severe systematic diseases or malignant tumor * female patients incline to be pregnant * being treated with corticosteroid, immunosuppressing drugs or cytotoxic drugs * poor compliance